A tyrosine kinase inhibitor (TKI) blocks tyrosine-kinase catalytic or signaling activity. In cancer research, EGFR-targeting TKIs aim to interrupt aberrant signaling and inhibit uncontrolled cancer-cell growth. section 8.1.1
Potency is represented computationally through two related measurements:
- IC50 is the concentration required to inhibit a biological process by half. section 8.1.1
- pIC50 is the negative logarithm of IC50; higher pIC50 indicates greater potency because it corresponds to lower IC50. section 8.1.1
- EGFR potency modeling can use 7,287 curated kinase bioactivities from Kinodata, derived from ChEMBL measurements. section 8.1.1
EGFR inhibitor discovery
A practical modeling task predicts EGFR pIC50 from curated kinase activity data. Raw ChEMBL IC50 values may be stored as nanomolar standard_value measurements, whereas the Kinodata subset already supplies pIC50 values. section 8.1.1
Figure 8.2 Map of human protein kinases, i.e., the Manning kinome tree, clustered based on sequence similarity into eight major groups [3].

Use the kinome tree to place EGFR within human protein-kinase groups clustered by sequence similarity. section 8.1.1
